{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:00:35Z","timestamp":1787504435231,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The incidence and prevalence of Parkinson\u2019s disease (PD) is expected to raise dramatically over the next decades. Gender-related differences are not yet widely recognized, particularly regarding the response to dopaminergic medications. To analyse gender differences in the clinical effects of safinamide, compared to placebo, in Chinese PD patients of the pivotal XINDI trial. The XINDI study was a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Patients were followed for 16\u00a0weeks receiving safinamide or placebo as add-on to levodopa. The primary efficacy endpoint was the change in the mean total daily OFF time. Secondary efficacy endpoints included total daily ON time, ON time with no\/non-troublesome dyskinesia, Unified Parkinson\u2019s Disease Rating Scale and Parkinson's Disease Questionnaire-39 items. A post-hoc analysis was performed to describe the efficacy of safinamide in both genders on motor symptoms, motor fluctuations and quality of life. 128 (42%) out of 305 patients enrolled were women and 177 (58%) men. Our additional analyses of the XINDI study have shown that safinamide, compared to placebo, was associated with improvements in motor symptoms, motor fluctuations and quality of life in both genders, with some differences in the response that did not reach statistical significance, possibly due to sample size limitation and post-hoc design of the study. The changes from baseline at week 16 were &gt;\u200950% higher in the females compared to males for the total daily OFF time (\u2212\u20091.149\u00a0h vs \u2212\u20090.764\u00a0h in males), the total daily ON time (1.283\u00a0h vs 0.441\u00a0h in males), the UPDRS total score (\u2212\u20098.300 points vs \u2212\u20095.253 points in males) and the UPDRS part II score (\u2212\u20092.574 points vs \u2212\u20091.016 points in males). The changes from baseline at week 16 were higher in the females compared to males in the \u201cADL\u201d domain (\u2212\u20096.965 points vs \u2212\u20095.772 points in males), the \u201cEmotional well-being\u201d domain (\u2212\u20096.243 points vs \u2212\u20094.203 in males), the \u201cStigma\u201d domain (\u2212\u20096.185 points vs \u2212\u20094.913 points in males) and the \u201cBodily discomfort\u201d domain (\u2212\u20095.196 points vs 1.099 points in males), while were higher in males in the \u201cMobility\u201d score (\u2212\u20096.523 points vs \u2212\u20094.961 points in females) and the \u201cCommunication\u201d score (\u2212\u20093.863 points vs \u2212\u20091.564 points in females). Safinamide was shown to improve PD symptoms and quality of life in both male and female Chinese patients. Possible differences in the response between genders need to be further studied in larger and different ethnic populations.<\/jats:p>","DOI":"10.1038\/s41598-023-48067-8","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:01:42Z","timestamp":1700751702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The effects of safinamide according to gender in Chinese parkinsonian patients"],"prefix":"10.1038","volume":"13","author":[{"given":"M. T.","family":"Pellecchia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Picillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Russillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Andreozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Oliveros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"48067_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"DT Dexter","year":"2013","unstructured":"Dexter, D. T. & Jenner, P. Parkinson disease: From pathology to molecular disease mechanisms. Free Radic. Biol. Med. 62, 132\u2013144 (2013).","journal-title":"Free Radic. Biol. Med."},{"key":"48067_CR2","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1517\/14656566.7.13.1715","volume":"7","author":"T M\u00fcller","year":"2006","unstructured":"M\u00fcller, T. & Russ, H. Levodopa, motor fluctuations and dyskinesia in Parkinson\u2019s disease. Expert Opin. Pharmacother. 7, 1715\u20131730 (2006).","journal-title":"Expert Opin. Pharmacother."},{"key":"48067_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109027","volume":"210","author":"MA Cenci","year":"2022","unstructured":"Cenci, M. A., Skovgard, K. & Odin, P. Non-dopaminergic approaches to the treatment of motor complications in Parkinson\u2019s disease. Neuropharmacology 210, 109027 (2022).","journal-title":"Neuropharmacology"},{"key":"48067_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF03033378","volume":"5","author":"TN Chase","year":"2003","unstructured":"Chase, T. N., Bibbiani, F. & Oh, J. D. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox. Res. 5, 139\u2013146 (2003).","journal-title":"Neurotox. Res."},{"issue":"11","key":"48067_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nrd.2018.136","volume":"17","author":"D Charvin","year":"2018","unstructured":"Charvin, D., Medori, R., Hauser, R. A. & Rascol, O. Therapeutic strategies for Parkinson disease: Beyond dopaminergic drugs. Nat. Rev. Drug Discov. 17(11), 804\u2013822 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"48067_CR6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00702-022-02465-w","volume":"129","author":"WH Jost","year":"2022","unstructured":"Jost, W. H. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease. J. Neural Transm. 129, 723\u2013736 (2022).","journal-title":"J. Neural Transm."},{"key":"48067_CR7","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1212\/WNL.67.7_suppl_2.S18","volume":"67","author":"C Caccia","year":"2006","unstructured":"Caccia, C. et al. Safinamide: From molecular target to a new anti-Parkinson drug. Neurology 67, S18\u2013S23 (2006).","journal-title":"Neurology"},{"key":"48067_CR8","first-page":"570","volume":"8","author":"PL Chazot","year":"2007","unstructured":"Chazot, P. L. Safinamide for the treatment of Parkinson\u2019s disease, epilepsy and restless legs syndrome. Curr. Opin. Investig. Drugs 8, 570\u2013579 (2007).","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"7","key":"48067_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1517\/13543784.17.7.1115","volume":"17","author":"M Onofrj","year":"2007","unstructured":"Onofrj, M., Bonanni, L. & Thomas, A. An expert opinion on safinamide in Parkinson\u2019s disease. Expert Opin. Investig. Drugs 17(7), 1115\u20131125 (2007).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"48067_CR10","first-page":"3","volume":"9","author":"J Kulisevsky","year":"2014","unstructured":"Kulisevsky, J. Emerging role of safinamide in Parkinson\u2019s disease therapy. Eur. Neurol. Rev. 9, 3\u20137 (2014).","journal-title":"Eur. Neurol. Rev."},{"issue":"2","key":"48067_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain, R. et al. Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov. Disord. 29(2), 229\u2013237 (2014).","journal-title":"Mov. Disord."},{"key":"48067_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","volume":"74","author":"AHV Schapira","year":"2017","unstructured":"Schapira, A. H. V. et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson\u2019s disease and motor fluctuations: A randomized clinical trial. JAMA Neurol. 74, 216\u2013224 (2017).","journal-title":"JAMA Neurol."},{"key":"48067_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","volume":"75","author":"N Hattori","year":"2020","unstructured":"Hattori, N., Tsuboi, Y., Yamamoto, A., Sasagawa, Y. & Nomoto, M. Efficacy and safety of safinamide as an add-on therapy to l-dopa for patients with Parkinson\u2019s disease: A randomized, double-blind, placebo-controlled, phase II\/III study. Parkinsonism Relat. Disord. 75, 17\u201323 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"10","key":"48067_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain, R. et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov. Disord. 29(10), 1273\u20131280 (2014).","journal-title":"Mov. Disord."},{"issue":"8","key":"48067_CR15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/jpm11080798","volume":"11","author":"D Santos Garcia","year":"2021","unstructured":"Santos Garcia, D. et al. Pain improvement in Parkinson\u2019s disease patients with safinamide: Results from the SAFINONMOTOR study. J. Pers. Med. 11(8), 798 (2021).","journal-title":"J. Pers. Med."},{"issue":"8","key":"48067_CR16","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00702-020-02218-7","volume":"127","author":"C Geroin","year":"2020","unstructured":"Geroin, C. et al. Effects of safinamide on pain in Parkinson\u2019s disease with motor fluctuations: An exploratory study. J. Neural Transm. 127(8), 1143\u20131152 (2020).","journal-title":"J. Neural Transm."},{"issue":"752632","key":"48067_CR17","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3389\/fneur.2021.752632.eCollection","volume":"12","author":"N Hattori","year":"2022","unstructured":"Hattori, N. et al. The effects of safinamide adjunct therapy on depression and apathy in patients with Parkinson\u2019s disease: Post-hoc analysis of Japanese Phase 2\/3 study. Front. Neurol. 12(752632), 2021. https:\/\/doi.org\/10.3389\/fneur.2021.752632.eCollection (2022).","journal-title":"Front. Neurol."},{"key":"48067_CR18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/brainsci11020232","volume":"11","author":"E Pena","year":"2021","unstructured":"Pena, E. et al. Impact of SAfinamide in Depressing symptoms in Parkinson\u2019s disease patients (SADness-PD study): A multicenter retrospective study. Brain Sci. 11, 232 (2021).","journal-title":"Brain Sci."},{"key":"48067_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.86652.eCollection","volume":"13","author":"J Kulisevsky","year":"2022","unstructured":"Kulisevsky, J. et al. A randomized clinical trial to evaluate the effects of safinamide on apathetic non-demented patients with Parkinson\u2019s disease. Front. Neurol. 13, 866502. https:\/\/doi.org\/10.3389\/fneur.2022.86652.eCollection (2022).","journal-title":"Front. Neurol."},{"key":"48067_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jocn.2021.07.011","volume":"91","author":"M Plastino","year":"2021","unstructured":"Plastino, M. et al. Effects of safinamide on REM sleep behavior disorder in Parkinson\u2019s disease: A randomized, longitudinal, cross-over pilot study. J. Clin. Neurosci. 91, 306\u2013312 (2021).","journal-title":"J. Clin. Neurosci."},{"issue":"2","key":"48067_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-019-0294-x","volume":"16","author":"S Meoni","year":"2020","unstructured":"Meoni, S., Macerollo, A. & Moro, E. Sex differences in movement disorders. Nat. Rev. Neurol. 16(2), 84\u201396 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"48067_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/bs.irn.2022.06.010","volume":"164","author":"G Arabia","year":"2022","unstructured":"Arabia, G., De Martino, A. & Moro, E. Sex and gender differences in movement disorders: Parkinson\u2019s disease, essential tremor, dystonia and chorea. Int. Rev. Neurobiol. 164, 101\u2013128 (2022).","journal-title":"Int. Rev. Neurobiol."},{"issue":"3","key":"48067_CR23","first-page":"104","volume":"3","author":"M Picillo","year":"2017","unstructured":"Picillo, M., Nicoletti, A., Fetoni, V., Garavaglia, B. & Pellecchia, M. T. The role of gender in Parkinson\u2019s disease. Ital. J. Gender-Specific Med. 3(3), 104\u2013108 (2017).","journal-title":"Ital. J. Gender-Specific Med."},{"key":"48067_CR24","volume-title":"Parkinson\u2019s Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care","author":"National Collaborating Centre for Chronic Conditions","year":"2006","unstructured":"National Collaborating Centre for Chronic Conditions. Parkinson\u2019s Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care (Royal College of Physicians, 2006)."},{"issue":"5","key":"48067_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"M Hoehn","year":"1967","unstructured":"Hoehn, M. & Yahr, M. Parkinsonism: Onset, progression and mortality. Neurology 17(5), 427\u2013442 (1967).","journal-title":"Neurology"},{"key":"48067_CR26","unstructured":"ICH Topic E10. Note for guidance on choice of control groups in clinical trials. CPMP\/ICH\/364\/96 January 2001."},{"issue":"11","key":"48067_CR27","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40263-022-00958-6","volume":"36","author":"W Qianqian","year":"2022","unstructured":"Qianqian, W. et al. The XINDI study: A randomized Phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in Chinese Parkinson\u2019s disease patients with motor fluctuations. CNS Drugs 36(11), 1217\u20131227 (2022).","journal-title":"CNS Drugs"},{"key":"48067_CR28","unstructured":"ISPE: The Good Automated Manufacturing Practice (GAMP) guide for validation of automated systems in pharmaceutical manufacture. GAMP 5: A risk-based approach to compliant GxP computerized systems. International society for pharmaceutical engineering (2008)."},{"key":"48067_CR29","unstructured":"World Health Organization-Drug Dictionary (WHO-DD), Upsala Monitoring Centre (2020)."},{"key":"48067_CR30","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA) version 23.1 (2020)."},{"issue":"2","key":"48067_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","volume":"23","author":"RA Hauser","year":"2000","unstructured":"Hauser, R. A. et al. A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia. Clin. Neuropharmacol. 23(2), 75\u201381 (2000).","journal-title":"Clin. Neuropharmacol."},{"key":"48067_CR32","first-page":"153","volume-title":"Recent Developments in Parkinson\u2019s Disease","author":"S Fahn","year":"1987","unstructured":"Fahn, S. & Elton, R. The Unified Parkinson\u2019s Disease Rating Scale. In Recent Developments in Parkinson\u2019s Disease Vol. 2 (eds Fahn, S. et al.) 153\u2013163 (McMellam Health Care Information, 1987)."},{"key":"48067_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.25383","volume":"28","author":"GT Stebbins","year":"2013","unstructured":"Stebbins, G. T. et al. How to identify tremor dominant and postural instability\/gait difficulty groups with the Movement Disorder Society Unified Parkinson\u2019s disease rating scale: Comparison with the Unified Parkinson\u2019s disease rating scale. Mov. Disord. 28, 668\u2013670 (2013).","journal-title":"Mov. Disord."},{"key":"48067_CR34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto, V., Jenkinson, C., Fitzpatrick, R. & Greenhall, R. The development and validation of a short measure of functioning and well-being for individuals with Parkinson\u2019s disease. Qual. Life Res. 4, 241\u2013248 (1995).","journal-title":"Qual. Life Res."},{"issue":"4","key":"48067_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<455::AID-SIM382>3.0.CO;2-Y","volume":"16","author":"E Russek-Cohen","year":"1997","unstructured":"Russek-Cohen, E. & Simon, M. N. Evaluating treatments when a gender by treatment interaction may exist. Stat. Med. 16(4), 455\u2013464 (1997).","journal-title":"Stat. Med."},{"issue":"1","key":"48067_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/archneurol.2009.295","volume":"67","author":"LM Shulman","year":"2010","unstructured":"Shulman, L. M. et al. The clinically important difference on the Unified Parkinson\u2019s Disease rating scale. Arch. Neurol. 67(1), 64\u201370 (2010).","journal-title":"Arch. Neurol."},{"issue":"11","key":"48067_CR37","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/mds.23135","volume":"25","author":"M Politis","year":"2010","unstructured":"Politis, M. et al. Parkinson\u2019s disease symptoms: The patient\u2019s perspective. Mov. Disord. 25(11), 1646\u20131651 (2010).","journal-title":"Mov. Disord."},{"key":"48067_CR38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3111\/13696998.2010.551164","volume":"14","author":"LI Findley","year":"2011","unstructured":"Findley, L. I. et al. The economic burden of advanced Parkinson\u2019s disease: An analysis of a UK patient dataset. J. Med. Econ. 14, 130\u2013139 (2011).","journal-title":"J. Med. Econ."},{"key":"48067_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF02740748","volume":"12","author":"F Blandini","year":"1996","unstructured":"Blandini, F., Porter, R. H. & Greenamyre, J. T. Glutamate and Parkinson\u2019s disease. Mol. Neurobiol. 12, 73\u201394 (1996).","journal-title":"Mol. Neurobiol."},{"key":"48067_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.909936","volume":"9","author":"V Conti","year":"2022","unstructured":"Conti, V. et al. Gender differences in levodopa pharmacokinetics in levodopa-na\u00efve patients with Parkinson\u2019s disease. Front. Med. 9, 909936. https:\/\/doi.org\/10.3389\/fmed.2022.909936 (2022).","journal-title":"Front. Med."},{"key":"48067_CR41","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3233\/JPD-212892","volume":"12","author":"M Picillo","year":"2022","unstructured":"Picillo, M. et al. Sex-related longitudinal change of motor, non-motor, and biological features in early Parkinson\u2019s disease. J. Parkinsons Dis. 12, 421\u2013436 (2022).","journal-title":"J. Parkinsons Dis."},{"issue":"13","key":"48067_CR42","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/mds.23834","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin, P. et al. Health-related quality-of-life scales in Parkinson\u2019s disease: Critique and recommendations. Mov. Disord. 26(13), 2371\u20132380 (2011).","journal-title":"Mov. Disord."},{"issue":"8","key":"48067_CR43","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.parkreldis.2014.04.023","volume":"20","author":"M Picillo","year":"2014","unstructured":"Picillo, M. et al. Gender differences in non-motor symptoms in early Parkinson\u2019s disease: A 2-years follow-up study on previously untreated patients. Parkinsonism Relat. Disord. 20(8), 850\u2013854 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"issue":"4","key":"48067_CR44","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3390\/jcm12041329","volume":"12","author":"D Santos-Garcia","year":"2023","unstructured":"Santos-Garcia, D. et al. Sex differences in motor and non-motor symptoms among Spanish patients with Parkinson\u2019s disease. J. Clin. Med. 12(4), 1329. https:\/\/doi.org\/10.3390\/jcm12041329 (2023).","journal-title":"J. Clin. Med."},{"issue":"3","key":"48067_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2517","volume":"12","author":"D Meng","year":"2022","unstructured":"Meng, D. et al. The quality of life in patients with Parkinson\u2019s disease: Focus on gender difference. Brain Behav. 12(3), e2517. https:\/\/doi.org\/10.1002\/brb3.2517 (2022).","journal-title":"Brain Behav."},{"issue":"1","key":"48067_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ane.13095","volume":"140","author":"Y Balash","year":"2019","unstructured":"Balash, Y., Korczyn, A. D., Migirov, A. A. & Gurevich, T. Quality of life in Parkinson\u2019s disease: A gender-specific perspective. Acta Neurol. Scand. 140(1), 17\u201322 (2019).","journal-title":"Acta Neurol. Scand."},{"key":"48067_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/gps1761","author":"D Santos-Garcia","year":"2022","unstructured":"Santos-Garcia, D. et al. Predictors of the change in burden, strain, mood and quality of life among caregivers of Parkinson\u2019s disease patients. Int. J. Geriatr. Psychiatry https:\/\/doi.org\/10.1002\/gps1761 (2022).","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"4","key":"48067_CR48","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3233\/JPD-171143","volume":"7","author":"C Cattaneo","year":"2017","unstructured":"Cattaneo, C. et al. Long-term effects of safinamide on mood fluctuations in Parkinson\u2019s disease. J. Parkinsons Dis. 7(4), 629\u2013634 (2017).","journal-title":"J. Parkinsons Dis."},{"issue":"4","key":"48067_CR49","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s12325-018-0687-z","volume":"35","author":"C Cattaneo","year":"2018","unstructured":"Cattaneo, C., Kulisevsky, J., Tubazio, V. & Castellani, P. Long-term efficacy of safinamide on Parkinson\u2019s disease chronic pain. Adv. Ther. 35(4), 515\u2013522 (2018).","journal-title":"Adv. Ther."},{"key":"48067_CR50","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jocn.2021.05.056","volume":"90","author":"J Pagonabarraga","year":"2021","unstructured":"Pagonabarraga, J., Tinazzi, M., Caccia, C. & Jost, W. H. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson\u2019s disease: Clinical cases and a review of the literature. J. Clin. Neurosci. 90, 178\u2013183 (2021).","journal-title":"J. Clin. Neurosci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48067-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48067-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48067-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:02:22Z","timestamp":1700751742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48067-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["48067"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-48067-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MT Pellecchia, M Picillo, MC Russillo, V Andreozzi are members of the Scientific Advisory Board of Zambon S.p.A. C Cattaneo and C. Oliveros are employees at Zambon S.p.A. All authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20632"}}